Tergase®

Tergase®
Product Description

1. Component:   - Recombinant human hyaluronidase

2. Indication:   - Tergase® is a stand-alone pharmaceutical version of Recombinant human hyaluronidase which is currently under clinical trial aiming marketing approval in the 3Q of 2022 from MFDS, South Korea. Through the inherent functionality, it can be utilized in therapies of plastic surgery, orthopedic pain control, chemotherapy, ophthalmology,  etc.. 

3. Primary advantage:  - Tergase® is the secondly developed Recombinant human hyaluronidase in the world. - Extremely high purity (> 99%) than animal derived products (<40%)  
- Less risk from allergic reaction  
- No risk of animal disease transmission

Read more Show less

Ceres F&D Inc.

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
Company types
Manufacturer/Innovator
View company profile
Categories
more categories Show less

Ceres F&D Inc.

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
Company types
Manufacturer/Innovator
View company profile

More Products from Ceres F&D Inc. (1)

  • Tacrolimus

    Product Tacrolimus

    1. Purpose   - Immunosuppressant  

    2. Effects/Benefits   -  Primarily used to reduce the risk of organ rejection in patients with allogeneic organ transplantation. It is also used to treat autoimmune diseases, such as atopic dermatitis.  


    3. Ma...